Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | HRH2 | P25021 | 3/20 | 0.38 |
| ▸ | HRH1 | P35367 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4127866 | 0.97 | KCNH2 (0.47) | KCNH2MEN1KMT2ADRD3DRD2 | |
| SCHEMBL4133154 | 0.95 | KCNH2 (0.43) | KCNH2DRD3DRD2KDM4EALDH1A1 | |
| SCHEMBL4133463 | 0.90 | KCNH2 (0.54) | KCNH2DRD3DRD2KDM4EHRH2 | |
| SCHEMBL4133190 | 0.89 | KCNH2 (0.46) | KCNH2DRD3DRD2HTR2AKDM4E | |
| SCHEMBL4130153 | 0.88 | KCNH2 (0.51) | KCNH2DRD3DRD2HTR2AKDM4E | |
| SCHEMBL4137801 | 0.86 | KCNH2 (0.59) | KCNH2MEN1HRH2HRH1HRH3 | |
| SCHEMBL4134395 | 0.85 | KCNH2 (0.49) | KCNH2DRD3DRD2HTR2AKDM4E | |
| SCHEMBL1619391 | 0.85 | KCNH2 (0.48) | KCNH2KDM4EHRH3ALDH1A1HTT | |
| SCHEMBL3598224 | 0.84 | KCNH2 (0.57) | KCNH2MEN1HRH2HRH1HRH3 | |
| SCHEMBL4140849 | 0.83 | KCNH2 (0.56) | KCNH2MEN1HRH2HRH1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 6/4885MEN1 1955/4885KMT2A 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.